Multiple Sclerosis Clinical Trial
Optimizing Detection and Prediction of Changes in Cognitive Function in Multiple Sclerosis (MS)
The researchers will use technology-assisted ambulatory assessment techniques to examine cognitive dysfunction in people with Multiple Sclerosis (MS).
The researchers will determine if ambulatory assessments are sensitive to subtle declines in cognitive functioning. They will also explore the impact of modifiable factors, such as sleep, physical activity, mood, and somatic symptoms on cognitive function. These efforts will uncover behavioral and medical intervention methods. Finally, they will explore whether variability in cognitive functioning predicts short- and long-term changes in other patient-centered functional domains, social participation and physical functioning.
Are able to fluently converse and read in English.
Multiple Sclerosis (MS) diagnosis (confirmed from neurologist, all relapsing and progressive subtypes included)
Ambulate either independently or with the use of a cane or walker (or similar device) for at least 50% of the time at baseline
MS relapse within the past 30 days (may become eligible after 30 days; criteria used at T1, T2, and T3).
Inability to use study data collection tools (i.e., ActiGraph wrist-worn activity watch, smart phone app).
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 3 Locations for this study
Ann Arbor Michigan, 48109, United States More Info
Detroit Michigan, 48202, United States More Info
Seattle Washington, 98195, United States More Info
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.